KR20210038429A - 글리코겐 신타제 키나제 3 형태 베타 억제제를 사용한 특발성 폐 섬유증의 치료 - Google Patents

글리코겐 신타제 키나제 3 형태 베타 억제제를 사용한 특발성 폐 섬유증의 치료 Download PDF

Info

Publication number
KR20210038429A
KR20210038429A KR1020207035908A KR20207035908A KR20210038429A KR 20210038429 A KR20210038429 A KR 20210038429A KR 1020207035908 A KR1020207035908 A KR 1020207035908A KR 20207035908 A KR20207035908 A KR 20207035908A KR 20210038429 A KR20210038429 A KR 20210038429A
Authority
KR
South Korea
Prior art keywords
lower alkyl
ome
alkyl substituted
ing
fibroblasts
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020207035908A
Other languages
English (en)
Korean (ko)
Inventor
토리 에이. 터커
스티븐 이델
Original Assignee
액투에이트 테라퓨틱스 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 액투에이트 테라퓨틱스 인크. filed Critical 액투에이트 테라퓨틱스 인크.
Publication of KR20210038429A publication Critical patent/KR20210038429A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
KR1020207035908A 2018-05-17 2019-05-16 글리코겐 신타제 키나제 3 형태 베타 억제제를 사용한 특발성 폐 섬유증의 치료 Ceased KR20210038429A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862672864P 2018-05-17 2018-05-17
US62/672,864 2018-05-17
PCT/US2019/032639 WO2019222483A1 (en) 2018-05-17 2019-05-16 Treatment of idiopathic pulmonary fibrosis with glycogen synthase kinase 3 form beta inhibitors

Publications (1)

Publication Number Publication Date
KR20210038429A true KR20210038429A (ko) 2021-04-07

Family

ID=68541026

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020207035908A Ceased KR20210038429A (ko) 2018-05-17 2019-05-16 글리코겐 신타제 키나제 3 형태 베타 억제제를 사용한 특발성 폐 섬유증의 치료

Country Status (11)

Country Link
US (1) US12083098B2 (https=)
EP (1) EP3793545A4 (https=)
JP (2) JP7471660B2 (https=)
KR (1) KR20210038429A (https=)
CN (1) CN112437663A (https=)
AU (1) AU2019271285B2 (https=)
BR (1) BR112020023422A2 (https=)
CA (1) CA3100381A1 (https=)
IL (1) IL278761B2 (https=)
MX (1) MX2020012331A (https=)
WO (1) WO2019222483A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020415440A1 (en) * 2019-12-26 2022-08-04 Actuate Therapeutics, Inc. Compounds for the treatment of myelofibrosis
US20250325517A1 (en) * 2022-06-27 2025-10-23 Actuate Therapeutics, Inc. Oral dosage forms of elraglusib
CN117981712B (zh) * 2023-07-24 2025-02-28 南京鼓楼医院 一种腺病毒诱导肺纤维化急性加重动物模型的建立方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2622987C (en) 2005-09-20 2018-02-27 New York University Method of treating pulmonary disease with interferons
CA2673368C (en) 2006-12-19 2014-10-28 The Board Of Trustees Of The University Of Illinois 3-benzofuranyl-4-indolyl maleimides as potent gsk3 inhibitors for neurogenerative disorders
JP6021117B2 (ja) 2011-01-31 2016-11-02 ジェノア ファーマシューティカルズ，インク． エアロゾルのピルフェニドンおよびピリドンアナログの化合物、および、その使用
KR101862291B1 (ko) * 2011-04-12 2018-05-29 모레 매트릭스 인코포레이티드 이상 섬유모세포 증식 및 세포외 기질 침착을 특징으로 하는 질병, 질환, 또는 과정을 예방하거나 치료하기 위한 조성물 및 방법
US20160375006A1 (en) 2012-10-12 2016-12-29 The Broad Institute, Inc. Uses of paralog-selective inhibitors of gsk3 kinases
JP2015535233A (ja) 2012-10-31 2015-12-10 ガレクト・バイオテック・エイビイ ガレクチン−３のガラクトシド阻害剤及び肺線維症のためのその使用
WO2014165851A1 (en) 2013-04-05 2014-10-09 The Children's Hospital Of Philadelphia Transient up-regulation of myc in b-cell lymphomas
JP6799201B2 (ja) 2013-07-31 2020-12-16 アヴァリン ファーマ インク． エアロゾルチロシンキナーゼ阻害剤の化合物、及びその使用
US20170165230A1 (en) 2014-04-09 2017-06-15 Christopher Rudd Use of gsk-3 inhibitors or activators which modulate pd-1 or t-bet expression to modulate t cell immunity
JP6534098B2 (ja) 2014-09-12 2019-06-26 国立大学法人 鹿児島大学 成人ｔ細胞白血病治療薬
EP3665176B1 (en) * 2017-08-11 2024-01-24 Actuate Therapeutics Inc. Solid forms of 3-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5h[1,3]dioxolo[4,5-f]indol-7-yl)pyrrole-2,5-dione
PL3697794T3 (pl) * 2017-10-16 2026-04-07 Actuate Therapeutics Inc. Stałe postacie 3-(5-fluorobenzofuran-3-ylo)-4-(5-metylo-5h-[1,3]dioksolo[4,5-f]indol-7-ilo)pirolo-2,5-dionu

Also Published As

Publication number Publication date
CN112437663A (zh) 2021-03-02
JP7471660B2 (ja) 2024-04-22
US12083098B2 (en) 2024-09-10
JP2024069221A (ja) 2024-05-21
US20210212988A1 (en) 2021-07-15
EP3793545A4 (en) 2022-04-06
IL278761A (en) 2021-01-31
WO2019222483A1 (en) 2019-11-21
MX2020012331A (es) 2021-03-09
AU2019271285B2 (en) 2024-10-03
CA3100381A1 (en) 2019-11-21
EP3793545A1 (en) 2021-03-24
AU2019271285A1 (en) 2020-12-03
IL278761B1 (en) 2024-11-01
BR112020023422A2 (pt) 2021-02-17
IL278761B2 (en) 2025-03-01
JP2021523951A (ja) 2021-09-09

Similar Documents

Publication Publication Date Title
JP2024069221A (ja) グリコーゲンシンターゼキナーゼ３型β阻害剤による特発性肺線維症の治療
AU2018280118A1 (en) Compositions for the treatment of fibrosis
US11324742B2 (en) Treatment of demyelinating diseases
JP2022519777A (ja) 処置誘導性の胃腸傷害を防止又は処置する方法
Fang et al. G protein-coupled receptor kinase 2 as a novel therapeutic target for gland fibrosis of Sjögren’s syndrome
EP3849976B1 (en) A gaba a receptor ligand
KR20200141446A (ko) 감소된 3급-부탄올 수준을 갖는 약제학적 조성물
JP7825238B2 (ja) アミロイドペプチドバリアント
US20100317699A1 (en) Use of hedgehog agonists in the treatment of musculoskeletal-related disorders
US11186581B2 (en) 2-(1,3-dimethyl-2,6-dioxo-1,2,3,6-tetrahydro-7H-purin-7-yl)-N-(6-(2-hydroxyphenyl)pyridazin-3-yl)acetamide as a Wnt pathway modulator
US20220331301A1 (en) Cystic fibrosis transmembrane conductance regulator modulators for treating autosomal resessive polycystic kidney disease
US20240342169A1 (en) Use of ensartinib or salt thereof in treatment of disease carrying met 14 exon skipping mutation
EP4252750A1 (en) Pharmaceutical preservation of creb activation in the treatment of alzheimer's disease
WO2024091485A1 (en) Compositions and methods for treating or preventing pulmonary fibrosis
US20230406825A1 (en) Compounds, compositions thereof, and methods for treating er+ breast cancer
WO2025096754A1 (en) The use of enolase inhibitor pomhex for treatment of fibrosis
CN119775186A (zh) 用于肌病治疗的s1pr4调节剂化合物及其应用
CN119894515A (zh) 用黄体生成素受体激动剂治疗肥胖症的方法
HK40057209B (en) A gabaa receptor ligand
HK40057209A (en) A gabaa receptor ligand
EA042390B1 (ru) Способ терапевтического лечения фиброза
JP2014141472A (ja) １，３，５−トリアジン誘導体を有する線維化予防又は治療剤
BRPI1106969A2 (pt) composição contendo guanabenzeno para tratamento da amiloidose cutânea primária

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20201214

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20220509

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20240122

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20250121

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D